tbuckley/cabot-search huggingface dataset:
Phase II study of neoadjuvant chemoradiotherapy with cisplatin plus 5-fluorouracil and elective nodal irradiation for stage II/III esophageal squamous cell carcinoma: A 2-year follow up.
Authors: Ken Kato, Jun Hashimoto, Yoshinori Ito, Kengo Nagashina, Takashi Kojima, Hiroyuki Daiko, Tetsuo Akimoto, Yasuo Hamamoto, Hisayuki Matsushita, Susumu Katano, Hiroki Hara, Yoichi Tanaka, Yoshihiro Saito, Hiroyasu Igaki
Journal: Journal of Clinical Oncology (2014)

129 Background: Neoadjuvant chemotherapy with cisplatin (CDDP) plus 5-fluorouracil (5-FU) is considered the standard treatment for stage II/III esophageal squamous cell carcinoma (ESCC) in Japan. However, patient survival remains unsatisfactory and neoadjuvant chemoradiotherapy (NeoCRT) may improve the outcome of stage II/III ESCC patients. We conducted a feasibility study of NeoCRT with CDDP plus 5-FU and elective nodal irradiation in patients with stage II/III ESCC. Methods: Eligibility criteria included clinical stage II/III (UICC 6th, non-T4) ESCC, a Performance status (PS) of 0-1, and age of 20–75 years. Chemotherapy consisted of 2 courses of 5-FU infusion (1000 mg/m 2 , days 1–4) and a 2-h CDDP infusion (75 mg/m 2 , day 1), with a 4-week interval. Radiotherapy was concurrently administered to the primary tumor, metastatic lymph nodes, and regional lymph nodes (total dose of 41.4 Gy in 23 fractions. After completion of NeoCRT, transthoracic esophagectomy with extensive lymphadenectomy (&gt;D2) was performed. The primary endpoint was the completion rate of NeoCRT with R0 resection. Results: Thirty-three patients were enrolled in this study between July 2010 and June 2011 and 2 were determined to be ineligible. Characteristics of the 31 eligible patients included, a median age of 63 years (range, 40–73 years), male/female: 28/3, PS 0/1: 19/12, and cStage IIA/IIB/III: 2/10/19. Median observation time was 30.0month. In total, 29 patients (93.5%) underwent NeoCRT with R0 resection. Among the patients who underwent surgery, there was 1 treatment-related death, and the incidence of operative morbidity was similar to that in previous studies. According to RECIST, the overall response rate was 78% (14/18) after CRT. Pathological complete response was achieved in 13 patients (42%) who underwent esophagectomy. The 2 years recurrence free survival rate 69.8%, and 2 years survival rate was77.4%, respectively. Conclusions: NeoCRT was well tolerated and found to be highly promising. A randomized controlled trial (JCOG1109) comparing with neoadjuvant chemotherapy was started. Clinical trial information: UMIN000004223.
Myelodysplasia and acute myelogenous leukemia after myeloablative therapy with autologous stem-cell transplantation.
Authors: A Rohatiner
Journal: Journal of Clinical Oncology (1994)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1994.12.12.2521 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 7989924 Myelodysplasia and acute myelogenous leukemia after myeloablative therapy with autologous stem-cell transplantation. A RohatinerxA RohatinerSearch for articles by this author https://doi.org/10.1200/JCO.1994.12.12.2521 First Page PDF © 1994 by American Society of Clinical Oncology
Colony-Stimulating Factors for Febrile Neutropenia
Authors: Sebastiano Buti, Angelica Sikokis, Andrea Ardizzoni
Journal: New England Journal of Medicine (2013)

1. Rieger M, Osterborg A, Pettengell R, et al. Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study. Ann Oncol 2011;22:664-70. 2. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991; 324:808-15. 3. Castellino SM, Geiger AM, Mertens AC, et al. Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. Blood 2011;117:180616. 4. Kenney LB, Laufer MR, Grant FD, Grier H, Diller L. High risk of infertility and long term gonadal damage in males treated with high dose cyclophosphamide for sarcoma during childhood. Cancer 2001;91:613-21. 5. Longo DL. Radiation therapy in the treatment of Hodgkin’s disease — do you see what I see? J Natl Cancer Inst 2003;95:928-9.
Pelvic Examination
Authors: Alison Edelman, JoDee Anderson, Susanna Lai, Dana A V Braner, Ken Tegtmeyer
Journal: New England Journal of Medicine (2007)

This video will demonstrate how to perform a comprehensive pelvic examination, which includes an examination of the external genitalia, a Papanicolaou test, a bimanual examination, as well as a rectovaginal examination. Indications Women should undergo a pelvic examination when they have vulvar and or vaginal complaints such as pain, discharge, abnormal bleeding, itching, and/or a mass. A pelvic examination is also indicated when pregnancy is suspected or proven, and in women who have been exposed to sexually transmitted infections. Pap testing is the main screening tool for detecting precancerous lesions of the cervix, we will now highlight the American Cancer Society . . . .
Response to Comment on Sjöholm et al. Weight Change–Adjusted Effects of Gastric Bypass Surgery on Glucose Metabolism: 2- and 10-Year Results From the Swedish Obese Subjects (SOS) Study. Diabetes Care 2016;39:625–631
Authors: Kajsa Sjöholm, Lena M.S. Carlsson, Markku Peltonen
Journal: Diabetes Care (2016)

We are pleased that Spaniolas and Pories (1) take an interest in our work and that they agree that “weight loss is a key factor in the success of metabolic surgery.” However, they have concerns about the methods used to assess weight loss–adjusted effects of gastric bypass surgery on glucose metabolism. We agree and therefore discussed the issues raised by Spaniolas and Pories in detail in the conclusions section (2), including the use of fasting glucose values and lack of clamp data (limiting us …
Updated Results of a Phase II Randomized Study (ROMULUS) of Polatuzumab Vedotin or Pinatuzumab Vedotin Plus Rituximab in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma
Authors: Franck Morschhauser, Ian Flinn, Ranjana H Advani, Catherine S. Diefenbach, Kathryn Kolibaba, Oliver W. Press, Laurie H Sehn, Andy I Chen, Gilles Salles, Herve Tilly, Bruce D. Cheson, Sarit Assouline, Martin Dreyling, Anton Hagenbeek, Pier Luigi Zinzani, Sreeni Yalamanchili, Dan Lu, Cheryl Jones, Surai Jones, Yu-Waye Chu, Jeff P. Sharman
Journal: Blood (2014)
SPRINT Results in Older Patients
Authors: Aram V. Chobanian
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
AB0923 Is Adult Hypophosphatasia a Cardiovascular Risk Factor?
Authors: L. Riancho, M. García-Unzueta, J.A. Gόmez-Gerique, A. Corrales, J.A. Riancho
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Moyamoya disease (MMD) is a rare cerebrovascular disease usually characterized by progressive bilateral distal internal carotid artery stenosis or occlusion and its consequences. Direct (ie, extracranial–intracranial bypass) or indirect cerebral revascularization procedures are the most established and effective treatment strategies for MMD. The case history is presented of a patient with MMD with delayed severe intracranial and subarachnoid hemorrhage following intracranial carotid artery stent placement. <h3>Clinical presentation</h3> An 18-year-old women presented with a history of seizures, recurrent episodes of transient right hemiparesis and aphasia. Cerebral catheter angiography and perfusion CT scan with azetozaolamide challenge confirmed impaired left hemispheric perfusion due to severe bilateral carotid artery stenosis combined with pathological collaterals, consistent with moyamoya disease. Endovascular stenting of the left supraclinoidal internal cerebral artery was performed uneventfully. Five hours after treatment the patient presented with sudden headache, nausea and speech disorders and a CT scan revealed intracerebral and subarachnoid hemorrhage. Due to further rapid clinical deterioration, surgical removal of the hematoma and decompression were required. The patient9s poor neurological outcome did not improve during the 2-year follow-up period. <h3>Conclusion</h3> This case report illustrates a severe intracerebral and subarachnoid hemorrhage following intracranial stenting of the internal carotid artery in a young patient with MMD. Potentially this complication could be attributed to high perfusion pressure breakthrough phenomenon, a known complication after cerebral high-flow bypass surgery. The role of intracranial stenting, despite established revascularization procedures in patients with MMD, therefore remains highly questionable.
PTH-061 Vitamin D is associated with an increased risk of oesophageal adenocarcinoma but not its pre-cursor conditions
Authors: H G Mulholland, M M Cantwell, L A Anderson, B T Johnston, R G P Watson, L J Murray
Journal: Gut (2010)

<h3>Introduction</h3> Evidence is accumulating that vitamin D may be protective against the development of many cancers.1 There are notable exceptions in the literature though, demonstrating increased risks of oesophageal squamous cell carcinoma and oesophageal squamous dysplasia for individuals with the highest serum concentrations of 25-hydroxyvitamin D.23 Our aim was to explore the association between dietary vitamin D and related nutrients and the risk of oesophageal adenocarcinoma (OAC) and its pre-cursor conditions, Barrett9s oesophagus (BO) and reflux oesophagitis (RO). <h3>Methods</h3> In an all-Ireland case-control study conducted between March 2002 and July 2005, 218 OAC patients, 212 long-segment BO patients, 208 RO patients and 252 healthy population-based controls completed a 101-item food frequency questionnaire, in addition to providing other lifestyle information and medical histories. Multiple logistic regression analysis was applied to examine the association between vitamin D, calcium and dairy intake and disease risk, prior to and after adjustment for potential confounders. Stratified analyses were also conducted by body mass index status. <h3>Results</h3> OAC risk was significantly greater for individuals in the highest compared with the lowest tertile of vitamin D intake (OR 1.99, 95% CI 1.03 to 3.86, p for trend=0.02) after adjustment for potential confounders. This elevated risk appeared to be accentuated in overweight (OR 2.49, 95% CI 1.16 to 5.37) OAC patients, although formal tests for interaction were not significant. Vitamin D intake was unrelated to RO and BO risk. There were no significant associations observed for calcium or dairy intake and RO, BO or OAC risk. <h3>Conclusion</h3> A significant direct association was observed between vitamin D intake and OAC risk, which concurs with previous findings for oesophageal squamous cell carcinoma. Vitamin D intake was unrelated to RO and BO risk. No significant associations were found between calcium or dairy intake and the risk of these oesophageal lesions. Further research is needed before recommendations to establish dietary vitamin D guidelines are implemented.
Outbreaks of 2009 pandemic influenza A (H1N1) among long-term-care facility residents - three states, 2009.
Authors: W. Bamberg, N. Finkner, D. Guppy, D. Simmerly, E. Clement, S. Kogut, J. K. Schaffzin, A. Fiore, A. Srinivasan, N. Stone, A. Kallen, S. Hocevar
Journal: MMWR Morbidity and Mortality Weekly Report (2010)
The Virus of Hepatitis, Type B
Authors: William S. Robinson, Larry I. Lutwick
Journal: New England Journal of Medicine (1976)

Biologic Implications of HBs AG-Bearing ParticlesThe presence of circular DNA of uniform size in Dane particles makes this structure the leading candidate for the complete hepatitis B virion (HBV) among the recognized particles in infectious plasma. Its size is consistent with studies showing that the infectious agent for hepatitis B passes through a membrane filter with an average pore diameter of 52 nm.73 The estimated number of Dane particles in most serum from chronic HBs Ag carriers (108 to 109 per milliliter26) is consistent with the observation74 that inoculation of 1 ml of a 10–7 dilution of . . .
Inflammatory Bowel Disease
Authors: Daniel K. Podolsky
Journal: New England Journal of Medicine (1991)

ALTHOUGH the causes of the common forms of idiopathic inflammatory bowel disease remain unclear, considerable progress has been made in the identification of important pathophysiologic mechanisms since these disorders were last reviewed in the Journal.1 Newer epidemiologic and clinical surveys have further clarified the clinical features, natural history, and complications of inflammatory bowel disease. In addition, the work of clinical investigators in many centers has enlarged the therapeutic armamentarium used for these diseases. This review will highlight these recent developments and provide an overview of the current understanding of the pathogenesis, diagnosis, and management of inflammatory bowel disease. The . . .
DMSO Precipitates Tissue Destruction
Authors: J H Johnson, R R Baker, S Wood
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Brief Communication: B-Cell Origin of Hamster Lymphoid Tumors Induced by Simian Virus 40
Authors: John E. Coe, Ira Green
Journal: JNCI Journal of the National Cancer Institute (1975)

Two lymphoid neoplasms induced by simian virus 40 (SV40) in Syrian hamsters were analyzed for lymphocyte characteristics. The hymphocytes from both tumors contained membrane-bound Ig that was exclusively of 7Sgamma2 class. Furthermore, neither lymphoid tumor had a complement receptor. Thus both tumors oringinated from a particular B-cell population, which suggests that this B-cell type is associated with an SV40 receptor.
The Writing on the Wall
Authors: Prashant Vaishnava, John J. Ross, Amy L. Miller, Brian M. Wolpin
Journal: New England Journal of Medicine (2009)

A 52-year-old man with diabetes mellitus was admitted to the hospital after presenting to the emergency department with abdominal discomfort. His symptoms began 5 weeks earlier, when epigastric discomfort developed that did not radiate elsewhere. The pain was worse after eating and was associated with nausea and bloating that were partially relieved by belching. Two weeks before presentation...
17 β -Estradiol up-regulates UDP-glucuronosyltransferase 1A9 expression via estrogen receptor α
Authors: Sung-joon Cho, Miaoran Ning, Yanyan Zhang, Leah H. Rubin, Hyunyoung Jeong
Journal: Acta Pharmaceutica Sinica B (2016)

UDP-glucuronosyltransferase 1A9 (UGT1A9) is a major phase II enzyme responsible for elimination of drugs and endogenous molecules. Clinical data have shown increased elimination of UGT1A9 substrates in pregnant women or oral contraceptive users, but the role of estrogen in the regulation of UGT1A9 expression remains unknown. In this study, we investigated the effect of 17β-estradiol (E2) on UGT1A9 expression and the role of ERα in the transcriptional regulation of UGT1A9. E2 significantly increased UGT1A9 promoter activity in HepG2 cells in the presence of ERα. UGT1A9 induction by E2 was abrogated by antiestrogen ICI182,780 in HepG2 cells that constitutively express ERα. Results from transient transfection of ERα mutants into HepG2 cells demonstrated that mutation at DNA-binding domain of ERα abrogates increased UGT1A9 promoter activity by E2. Deletion and mutation assays of UGT1A9 promoter revealed a putative ERE located within -2262/-1987 region. Examination of healthy human liver tissues revealed significantly higher UGT1A9 expression in women as compared to men. Together, these findings provide a mechanistic basis for the previous clinical reports and may shed a light on identifying sources for inter-individual variability in UGT1A9-mediated drug metabolism.
RADICAL CURE OF INGUINAL HERNIA
Authors: J. O'Conor
Journal: BMJ (1914)

I UZMDICAL JOURNAL 3 pulls up easily, and the intestines fall back-into the abdomen; usually no packing is required.The injection, of course, adds to the dluration of tlle operation, but, when once accustomed to it, it can -rarely add more than five, or at the most ten, minutes.Part of this time is regained by the ease of operating, and in any case it is of no consequence, for the patient's condition is improved by it.Tllere lhas been, however, one exception to tllis: An elderly woman of very poor fibre, weakened
MPTH-16GENOMIC AND CLINICAL CHARACTERISTICS OF NF1-MUTATED GLIOBLASTOMA (GBM)
Authors: Andrew Lin, Ingo Mellinghoff, Christian Grommes
Journal: Neuro-Oncology (2015)

BACKGROUND: Mutations in the neurofibromin 1 (NF1) tumor suppressor gene are common in GBM. We sought to characterize the mutational and clinical landscape of these NF1-mutated GBMs. METHODS: IRB approval was granted to collect clinical information on GBMs with NF1 and EGFR alterations (control group) identified by hybridization capture-based next-generation sequencing. Progression free survival (PFS) was based on the Macdonald criteria. RESULTS: 35 GBMs harboring a NF1-mutation were identified in 17 men and 18 women. Median age was 57 (range 33-76); 9% underwent biopsy and 91% resection. All patients received radiotherapy, 97% received concurrent temozolomide, and 88% received adjuvant temozolomide. Genomic alterations in NF1 were evenly distributed throughout the gene without hot spot mutations. Associated genetic alterations occurred in PTEN (60%), TERT promoter (60%), CDKN2A/B locus (51%), TP53 (31%), PIK3CA (20%), RB1 (14%), and STAG2 (11%). Contrast enhancement during the first three months post-radiotherapy was identified in 74% of NF1-mutated GBMs and 57% of EGFR-altered GBMs, resulting in a difference in PFS: 3.3 vs. 4.8 months (p = 0.018)–without a difference in overall survival (OS), p = 0.61. Furthermore, a shorter PFS was identified in NF1-mutated GBMs with a loss of CDKN2A/B (3.2 vs 5.1 mo, p = 0.006) with a trend towards shorter survival (p = 0.14). There was no difference in PFS in EGFR-altered GBMs with a loss of CDKN2A/B (p = 0.71). 7/7 tumors with NF1 mutations and early contrast enhancement were hypermetabolic on PET and 17/18 tumors with early contrast enhancement were hyperperfused on MR perfusion–there was no difference in OS when patients with early contrast enhancement were continued on temozolomide rather than changed to salvage therapy (p = 0.76). CONCLUSION: NF1-mutated GBMs are associated with PTEN, CDKN2A/B, and TP53 mutations and have a higher rate of early contrast enhancement post-radiotherapy, particularly the tumors with associated loss of the CDKN2A/B locus.
Toxigenic Turista
Authors: Michael H. Merson
Journal: New England Journal of Medicine (1975)

Before departing on their long awaited vacation, visit, or business trip to a foreign land, many Americans pack an ample supply of various pharmaceuticals for treatment of an anticipated diarrheal illness. The medications that they carry are as varied as the names given this affliction. Not to be taken lightly, this illness, most commonly referred to as travelers' diarrhea, has compromised the activity of American troops stationed in Europe and Vietnam, limited the performance of Olympic athletes, and altered the best laid plans of scientific visitors to international congresses.The clinical syndrome of travelers' diarrhea generally follows a typical pattern. . . .
Regulatory approval of new medical devices: cross sectional study
Authors: Hani J Marcus, Christopher J Payne, Archie Hughes-Hallett, Adam P Marcus, Guang-Zhong Yang, Ara Darzi, Dipankar Nandi
Journal: BMJ (2016)

To investigate the regulatory approval of new medical devices. Cross sectional study of new medical devices reported in the biomedical literature. PubMed was searched between 1 January 2000 and 31 December 2004 to identify clinical studies of new medical devices. The search was carried out during this period to allow time for regulatory approval. Articles were included if they reported a clinical study of a new medical device and there was no evidence of a previous clinical study in the literature. We defined a medical device according to the US Food and Drug Administration as an "instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article." Type of device, target specialty, and involvement of academia or of industry for each clinical study. The FDA medical databases were then searched for clearance or approval relevant to the device. 5574 titles and abstracts were screened, 493 full text articles assessed for eligibility, and 218 clinical studies of new medical devices included. In all, 99/218 (45%) of the devices described in clinical studies ultimately received regulatory clearance or approval. These included 510(k) clearance for devices determined to be "substantially equivalent" to another legally marketed device (78/99; 79%), premarket approval for high risk devices (17/99; 17%), and others (4/99; 4%). Of these, 43 devices (43/99; 43%) were actually cleared or approved before a clinical study was published. We identified a multitude of new medical devices in clinical studies, almost half of which received regulatory clearance or approval. The 510(k) pathway was most commonly used, and clearance often preceded the first published clinical study.